La vendita allo scoperto per Amphastar Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Amphastar Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Amphastar Pharma (NASDAQ:AMPH) Azioni, Report sulle vendite allo scoperto

Amphastar Pharma

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals Inc

Amphenol Corp

Wells Fargo analyst Cerena Chen maintains Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Overweight and lowers the price target from $40 to $35.

News

Price Target

Analyst Ratings

AMPH

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $35

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.69 by 7.25 percent. This is a 28.85 percent decrease over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $170.53 million which missed the analyst consensus estimate of $172.94 million by 1.39 percent. This is a 0.76 percent decrease over sales of $171.84 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Amphastar Pharma Q1 Adj. EPS $0.74 Beats $0.69 Estimate, Sales $170.53M Miss $172.94M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Amphastar Pharma will report an earnings per share (EPS) of $0.69.
Investors in Amphastar Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.02 in the last quarter, leading to a 9.72% drop in the share price on the following day.
Here's a look at Amphastar Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.77</td>
<td>0.74</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.92</td>
<td>0.96</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-14.000000000000002%</td>
<td>13.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543855_0.png" alt="eps graph" />
<h3>Amphastar Pharma Share Price Analysis</h3>
Shares of Amphastar Pharma were trading at $25.12 as of May 05. Over the last 52-week period, shares are down 41.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Amphastar Pharma</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Amphastar Pharma.
Analysts have given Amphastar Pharma a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $32.0, indicating a potential 27.39% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Innoviva, Pacira BioSciences and Ocular Therapeutix, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Innoviva, with an average 1-year price target of $55.0, suggesting a potential 118.95% upside.</li>
<li>Analysts currently favor an Buy trajectory for Pacira BioSciences, with an average 1-year price target of $44.6, suggesting a potential 77.55% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 36.98% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Innoviva, Pacira BioSciences and Ocular Therapeutix, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Innoviva</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$84.64M</td>
<td>2.99%</td>
</tr>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Amphastar Pharma ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the top. The consensus rating for Amphastar Pharma is Neutral.
<h3>Delving into Amphastar Pharma's Background</h3>
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
<h3>Understanding the Numbers: Amphastar Pharma's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Amphastar Pharma's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 4.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amphastar Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amphastar Pharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.43%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Amphastar Pharma adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/AMPH/earnings">To track all earnings releases for Amphastar Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Amphastar Pharma

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Amphastar Pharmato Hold

Amphastar's Subsidiary International Medication Systems Receives FDA Drug Shortage Assistance Award For Efforts In Alleviating Critical Drug Shortages

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Neutral and lowers the price target from $36 to $32.

Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $32

WIIM

Amphastar Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results.

On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 94 cents</a>.
Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/ac44024962/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-ended-dece" rel="noreferrer noopener">inhalation, and intranasal products</a>.
The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million.
Jack Zhang, Amphastar&#8217;s President and Chief Executive Officer, commented, &#8220;We are incredibly proud that in 2024, we exceeded our long-term goal of achieving&nbsp;$100 million&nbsp;in annual sales for Primatene MIST, and we look forward to continuing to grow the brand. Furthermore, BAQSIMI&nbsp;showed strong factory sales growth of 12% compared to the fourth quarter of last year. As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>
Primatene MIST&nbsp;exceeded the long-term goal of&nbsp;$100 million&nbsp;in annual sales (around $29 million in the quarter), while&nbsp;BAQSIMI&nbsp;contributed&nbsp;$41.8 million&nbsp;in direct sales during the fourth quarter alone ($126.9 million&nbsp;for the full year).
JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays.
Analyst Ekaterina Knyazkova sees limited downside for the stock as Amphastar shares are now in the low $30s. Primatene MIST and Baqsimi continue growing, with the current valuation reflecting little value for Amphastar&#8217;s extensive R&amp;D efforts and pipeline.
JP Morgan maintains the Overweight rating for Amphastar&#8217;s stock with a <a target="_blank" href="https://www.benzinga.com/quote/AMPH/analyst-ratings" rel="noreferrer noopener">price target of $45.</a>
Price Action: AMPH stock is down 8.35% at $28.86 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44046550/nayax-acquires-uppay-in-53m-deal-adding-25000-self-service-points-to-its-brazilian-network" target="_blank" rel="noreferrer noopener">Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Guidance

Health Care

Movers

Trading Ideas

General

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $0.94 by 2.13 percent. This is a 4.55 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $186.500 million which missed the analyst consensus estimate of $188.810 million by 1.22 percent. This is a 4.71 percent increase over sales of $178.105 million the same period last year.

Amphastar Pharma Q4 2024 Adj. EPS $0.92 Misses $0.94 Estimate, Sales $186.500M Miss $188.810M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

ALEX

ALHC

ALKT

ALTM

AMBP

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">West Pharmaceutical Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</h3>
<ul>
<li>On Feb. 13, West Pharmaceutical Services reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72. The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $748.8 million, beating the consensus of $740.47 million. The company's stock fell around 39% over the past month and has a <a href="https://www.benzinga.com/quote/WST">52-week low of $197.01</a>.</li>
<li>RSI Value: 21.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WST Price Action: Shares of West Pharmaceutical gained 2.6% to trade at $208.92 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest WST <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png" alt="" class="wp-image-793688" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-768x705.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Amphastar Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Amphastar Pharmaceuticals will release results for its fourth quarter results, after the market closes on Thursday, Feb. 27, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/AMPH">has a 52-week low</a> of $30.34.</li>
<li>RSI Value: 25.3</li>
<li>AMPH Price Action: Shares of Amphastar Pharmaceuticals fell 0.8% to close at $120.92 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">AMPH stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="857" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png" alt="" class="wp-image-793689" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-300x298.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-768x763.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43890670/this-unity-software-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Long Ideas

Markets

Top 2 Health Care Stocks That May Rocket Higher This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst David Amsellem downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowered the price target from $66 to $36. Amphastar Pharma shares closed at $33.39 on Monday. <a href="https://www.benzinga.com/quote/AMPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Peter Arment downgraded Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Outperform to Neutral but raised the price target from $20 to $26. Triumph Group shares closed at $25.10 on Monday. <a href="https://www.benzinga.com/quote/TTGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik downgraded the rating for Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and lowered the price target from $125 to $111. Ollie&#8217;s Bargain shares closed at $107.63 on Monday. <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and cut the price target from $20.5 to $15. Calumet shares closed at $18.34 on Monday. <a href="https://www.benzinga.com/quote/CLMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Trevor Allinson downgraded the rating for American Woodmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) from Outperform to Peer Perform. American Woodmark shares closed at $75.65 on Monday. <a href="https://www.benzinga.com/quote/AMWD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OLLI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png" alt="" class="wp-image-764859" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Downgrades

Pre-Market Outlook

CLMT

OLLI

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Piper Sandler analyst David Amsellem downgrades Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowers the price target from $66 to $36.

Piper Sandler Downgrades Amphastar Pharma to Neutral, Lowers Price Target to $36

Amphastar Pharma shares are trading lower after the company reported worse-than-expected Q3 financial results.

Buybacks

Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.99 by 3.03 percent. The company reported quarterly sales of $191.20 million which missed the analyst consensus estimate of $194.69 million by 1.79 percent. This is a 5.90 percent increase over sales of $180.56 million the same period last year.

Amphastar Pharma Q3 2024 Adj EPS $0.96 Misses $0.99 Estimate, Sales $191.20M Miss $194.69M Estimate

JP Morgan notes that while there&#8217;s a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
The group&#8217;s core fundamentals have strengthened, buoyed by a more stable environment for generic and established brand pricing, which helps mitigate the usual erosion in base business prices.
However, growth in the overall sector remains modest, with most companies experiencing a top-line compound annual growth rate (CAGR) of 0-2%.
Additionally, valuations have recovered, with most stocks now trading near their historical averages.
JP Morgan writes that Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) continues to be the primary focus among investors in the group, with sentiment growing more bullish.
The analyst <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a>, as the market seems to have fully accounted for the company&#8217;s branded pipeline. Additionally, JP Morgan is cautious about Teva&#8217;s U.S. generic business compared to market expectations.
The analyst has given Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) <a target="_blank" href="https://www.benzinga.com/quote/VTRS/analyst-ratings" rel="noreferrer noopener">a Neutral rating</a>, citing its stable fundamentals and low valuation amidst uncertainties in business development.
Meanwhile, JP Morgan holds a <a target="_blank" href="https://www.benzinga.com/quote/PRGO/analyst-ratings" rel="noreferrer noopener">more optimistic view</a>, an Overweight rating on Perrigo Co plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>), noting the potential for earnings per share (EPS) to rebound to the low-mid $3 range soon due to currently low market sentiment. With shares currently trading at a significantly lower price than other consumer sector peers, the analyst believes there is substantial potential for an increase in valuation multiples as the recovery progresses.
Similarly, positive <a target="_blank" href="https://www.benzinga.com/quote/AMPH/analyst-ratings" rel="noreferrer noopener">prospects are seen</a> for Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), where the analyst anticipates a promising series of catalysts leading into 2024/2025. Keeps Overweight rating.
JP Morgan is adjusting several ratings, which are relative to each other. The analyst has changed Amneal Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) to <a target="_blank" href="https://www.benzinga.com/quote/AMRX/analyst-ratings" rel="noreferrer noopener">Neutral from Underweight</a> and Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) to <a target="_blank" href="https://www.benzinga.com/quote/OGN/analyst-ratings" rel="noreferrer noopener">Underweight from Neutral</a>.
For Amneal, the company&#8217;s success in launching new products suggests the potential for improved financial forecasts, which could bolster the stock.
Conversely, Organon&#8217;s stock price has increased 60% year-to-date. Although its valuation still appears low, the recent price surge suggests more attractive opportunities within the sector may exist.
Price Action: OGN stock is down 2.95% at $20.73, and AMRX stock is down 1.42% at $8.33 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40752830/robinhood-shifted-from-meme-stock-to-market-contender-amid-new-products-and-global-" target="_blank" rel="noreferrer noopener">Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock</a>.</li>
</ul>

Biotech

Equities

Large Cap

AMRX

PRGO

TEVA

VTRS

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

Amphastar Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Events

Press Releases

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025

Comments

Amphastar Pharma

Vendite allo scoperto

Amphastar Pharma (NASDAQ:AMPH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO